GlaxoSmithKline plc announces changes to its Board and Committees

Issued: Wednesday 26 September 2012, London, UK -- GlaxoSmithKline plc today announces the following changes to its Board and Committee structure.

In January 2012, GSK announced that Sir Robert Wilson would not stand for re-election to the Board at the Company's AGM in 2013. Given the recent refreshment of the Board and that two long-standing Board members will be standing down from the Board by  May 2013, Sir Robert has agreed to stand for re-election to the Board for one further year from May 2013, before stepping down from the Board at the Company's AGM in May 2014.  Sir Robert will provide continuity as new Board members settle in to their roles given his significant knowledge of the Company's business affairs.  The Board has confirmed that Sir Robert Wilson continues to demonstrate the characteristics of independence in carrying out his role.

Mr Larry Culp has decided to stand down from the Board with effect from 30th September 2012 following nine years service.  It was previously announced that he would stand down at the Company's AGM in May 2013.

In addition, the following changes have been made to the Board's Committee membership:

· Mr Tom de Swaan and Professor Sir Roy Anderson have been appointed members of the Nomination Committee with effect from 1st October 2012.

· Ms Lynn Elsenhans has been appointed a member of the Corporate Responsibility Committee with effect from 1st October 2012.

· Ms Judy Lewent and Dr Stephanie Burns have been appointed members of the Remuneration Committee with effect from 1st January 2013 and 1st May 2013 respectively.

· Ms Jing Ulrich has been appointed a member of the Audit & Risk Committee with effect from 1st May 2013. Professor Sir Roy Anderson will step down from the Audit & Risk Committee with effect from 1st May 2013.

Commenting on the changes, Sir Christopher Gent, Chairman of GSK, said:

"I am pleased that Sir Robert has agreed to remain on the Board for a further year to contribute his advice and guidance as we continue the process of Board renewal.

I would also like to thank Larry for the very strong contribution he has made.  He has served on the Board with distinction during the nine years he has been a Director. I would like to wish him well for his future endeavours."

Victoria Whyte
Company Secretary
26 September 2012


GSK Board of Directors with effect from 1st October 2012

Sir Christopher Gent               Non-Executive Chairman

Sir Andrew Witty                     Chief Executive Officer

Simon Dingemans                  Chief Financial Officer

Moncef Slaoui                         Executive Director, Chairman, Research & Development

Professor Sir Roy Anderson   Independent Non-Executive Director

Dr Stephanie Burns                Independent Non-Executive Director

Ms Stacey Cartwright             Independent Non-Executive Director

Sir Crispin Davis                     Independent Non-Executive Director

Ms Lynn Elsenhans                Independent Non-Executive Director

Ms Judy Lewent                     Independent Non-Executive Director

Sir Deryck Maughan              Independent Non-Executive Director**

Dr Daniel Podolsky                 Independent Non-Executive Director

Mr Tom de Swaan                  Independent Non-Executive Director

Ms Jing Ulrich                         Independent Non-Executive Director

Sir Robert Wilson                    Senior Independent Non-Executive Director*

* Senior Independent Director until 1 May 2013

** Senior Independent Director with effect from 1 May 2013.

GlaxoSmithKline- one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live

GlaxoSmithKline Enquiries:

UK Media enquiries:               David Mawdsley         +44 (0) 20 8047 5502 (London)

                                                Stephen Rea               +44 (0) 20 8047 5502 (London)

                                                Sarah Spencer            +44 (0) 20 8047 5502 (London)

                                                David Daley                +44 (0) 20 8047 5502 (London)

US Media enquiries:               Kevin Colgan              +1 919 483 2839         (North Carolina)

Melinda Stubbee         +1 919 483 2839         (North Carolina)

                                                Sarah Alspach                        +1 919 483 2839         (Washington, DC)

                                                Jennifer Armstrong     +1 919 483 2839         (Philadelphia) 

Analyst/Investor enquiries:      Sally Ferguson            +44 (0) 20 8047 5543 (London)

                                                Tom Curry                  + 1 215 751 5419        (Philadelphia) 

                                                Gary Davies                +44 (0) 20 8247 5503 (London)

                                                Jeff McLaughlin          + 1 215 751 7002        (Philadelphia)

                                                Ziba Shamsi                +44 (0) 20 8047 3289 (London)

To read more People News articles, click here.